ReviewProbiotics and antimicrobial proteins2026
Anticancer Bioactive Peptides from Plants: Sources, Action Mechanisms, and Potential Superiority to Conventional Chemotherapy.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer continues to be a major global health challenge, with existing treatments often causing severe side effects, drug resistance, and high costs. Plant-derived anticancer peptides (PDACPs) have emerged as a promising alternative due to their high specificity, multi-target mechanisms, and safety profile. This review summarizes the sources (e.g., legumes, cereals, and medicinal plants), mechanisms of action, and therapeutic potential of PDACPs, highlighting their role in apoptosis induction, cell cycle arrest, anti-angiogenesis, and metastasis inhibition. Mechanistic investigations reveal that PDACPs exert anticancer effects through multiple pathways, including the induction of apoptosis via mitochondrial membrane disruption and the upregulation of pro-apoptotic factors, the inhibition of cell proliferation by arresting cell-cycle progression, the suppression of angiogenesis through the downregulation of vascular endothelial growth factor signaling, and the disruption of tumor-associated membrane integrity. Preclinical studies suggest that, compared to conventional chemotherapeutics, PDACPs may offer advantages such as enhanced tumor selectivity, reduced off-target toxicity, and diminished likelihood of resistance development. We also discuss current challenges in peptide stability, delivery, and large-scale production, and propose strategies, such as nanoparticle encapsulation, to enhance clinical viability. This comprehensive synthesis underscores the potential of PDACPs as next-generation anticancer therapeutics and paves the way for translational development.
Indexed as
Identifiers
40974531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.